Sanofi

News

MSD preparing to take on Beyfortus with RSV antibody

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting

News

Foundation stone ceremony at Orano Med's ATLab plant in France, set to be the first industrial-scale pharma facility in Europe for lead-212 isotopes

Sanofi invests €300m in Orano Med's lead-based radioligands

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea

News

Sanofi in talks to sell stake in consumer health spinout

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.

News

Sanofi's Dupixent scores double COPD win in US, China

Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.

News

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.

News

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data

MSD preparing to take on Beyfortus with RSV antibody

Sanofi invests €300m in Orano Med's lead-based radioligands

Sanofi in talks to sell stake in consumer health spinout

Sanofi's Dupixent scores double COPD win in US, China

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's tolebrutinib cuts MS progression by 31% in trial

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

Sanofi

Editor's Picks